目的 探讨分化型甲状腺癌[differentiated thyroid carcinoma，DTC]术后131I联合利可君治疗的可行性，以提高甲状腺癌患者接受治疗期间的依从性和疗效。方法 回顾性分析 2007年1月至2013年3月167例DTC 术后残留、局部复发、淋巴结转移和/或全身转移的患者在接受131I治疗期间联合应用利可君治疗的效果。根据131I治疗前未给予利可君，131I治疗后给予利可君20 mg/次，tid为A组47例； 131I治疗前未给予利可君，131I治疗后给予利可君40 mg/次，tid为B组：； 131I治疗前为预防WBC和PLT降低给予利可君20mg/次，tid，治疗后给予利可君80 mg/次为C组。结果 131I治疗和联合利可君治疗DTC患者167例，A、B、C三组患者在样本量、年龄相近、131I治疗前WBC、PLT水平的差异均无统计学意义（P>0.05）；3组患者131I治疗后的WBC和PLT呈不同程度的变化，其中A组和B组的WBC和PLT可见明显减少(P<0.05)，C组未见明显变化（P>0.05）；131I治疗分化型甲状腺癌术后残留、局部复发或远处转移的疗效可靠。结论 分化型甲状腺癌术后131I治疗期间联合利可君治疗是预防WBC和PLT减少及骨髓抑制的有效方法。

Objective To investigate the feasibility of combined 131I and Leucoge curing the differentiated thyroid carcinoma after operation and in order to enhance the therapeutic compliance and efficacy in the thyroid cancer patients during therapy period. Methods The information was collected and then had a retrospective analysis in 167 differentiated thyroid cancer patients with postoperative residual thyroid tissue, local recurrence or lymph node and systemic metastases. Total 167 patients were divided into 3 groups that was based on giving Leucogen tablets 20mg tid (Group A, n=47), 40mg tid (Group B, n=54) and 80mg tid (Group C, n=66) following post-treatment with 131I. The therapeutic effectiveness of 131I combined with Leucoge was evaluated during therapy period. Results There were no change between three groups in sample size, age, WBC and PLT before curing of 131I (P>0.05). The level of WBC and PLT in three groups had selective change after 131I treatment. The WBC and PLT levels in Group A and Group B had significantly decreased (P<0.05) and no effect in Group C (P>0.05). The efficacy of 131I on differentiated thyroid carcinoma with postoperative residual thyroid tissue, local and distant metastases was confirmed in this study. Conclusion The combination of 131I and Leucoge is an effective cure on postoperative differentiated thyroid carcinoma to prevent the decrease of WBC and PLT as well as bone marrow suppression.